Keywords: merck, serono, initiates, ph, ii, trial, cladribine

Merck Serono initiates Ph II trial of cladribine

Article | 29 January 2007

Print This

German-Swiss drugmaker Merck Serono has initiated a Phase II study to evaluate the safety, tolerability and efficacy of two dose ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in